MA43724B1 - Molécules bispécifiques de cellules t activées par une protéase - Google Patents

Molécules bispécifiques de cellules t activées par une protéase

Info

Publication number
MA43724B1
MA43724B1 MA43724A MA43724A MA43724B1 MA 43724 B1 MA43724 B1 MA 43724B1 MA 43724 A MA43724 A MA 43724A MA 43724 A MA43724 A MA 43724A MA 43724 B1 MA43724 B1 MA 43724B1
Authority
MA
Morocco
Prior art keywords
protease
idiotype
activatable
bispecific
specific polypeptides
Prior art date
Application number
MA43724A
Other languages
English (en)
Other versions
MA43724A (fr
Inventor
Pablo Umana
Christian Klein
Kay-Gunnar Stubenrauch
Peter Bruenker
Rebecca Croasdale-Wood
Juergen Michael Schanzer
Martina Geiger
Eric Sullivan
Jigar Patel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA43724A publication Critical patent/MA43724A/fr
Publication of MA43724B1 publication Critical patent/MA43724B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

La présente invention concerne de manière générale de nouvelles molécules bispécifiques d'activation de cellules t activables par une protéase et de nouveaux polypeptides spécifiques d'un idiotype agissant comme des fractions de masquage. La présente invention concerne également des polynucléotides codant ces molécules bispécifiques d'activation des cellules t activables par une protéase et ces polypeptides spécifiques d'un idiotype, et des vecteurs et des cellules hôtes comprenant ces polynucléotides. L'invention concerne en outre des procédés de production des molécules bispécifiques d'activation des cellules t activables par une protéase et des polypeptides spécifiques d'un idiotype selon l'invention, et des procédés d'utilisation de ces molécules bispécifiques d'activation des cellules t activables par une protéase et des polypeptides spécifiques d'un idiotype dans le cadre du traitement d'une maladie.
MA43724A 2016-03-22 2017-03-20 Molécules bispécifiques de cellules t activées par une protéase MA43724B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16161740 2016-03-22
PCT/EP2017/056556 WO2017162587A1 (fr) 2016-03-22 2017-03-20 Molécules bispécifiques de cellules t activées par une protéase

Publications (2)

Publication Number Publication Date
MA43724A MA43724A (fr) 2018-11-28
MA43724B1 true MA43724B1 (fr) 2023-06-28

Family

ID=55646332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43724A MA43724B1 (fr) 2016-03-22 2017-03-20 Molécules bispécifiques de cellules t activées par une protéase

Country Status (14)

Country Link
EP (1) EP3433280B1 (fr)
KR (1) KR102444614B1 (fr)
CN (1) CN108884170A (fr)
AR (2) AR107946A1 (fr)
AU (1) AU2017237376B2 (fr)
BR (1) BR112018016281A2 (fr)
CA (1) CA3012422A1 (fr)
CO (1) CO2018007556A2 (fr)
CR (1) CR20180453A (fr)
MA (1) MA43724B1 (fr)
PE (1) PE20181891A1 (fr)
PT (1) PT3433280T (fr)
SG (1) SG11201808085WA (fr)
WO (1) WO2017162587A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
US11168139B2 (en) 2016-11-28 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
MA47613A (fr) * 2017-02-22 2020-01-01 Aleta Biotherapeutics Inc Compositions et procédés de traitement du cancer
AU2018347607A1 (en) 2017-10-14 2020-03-26 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
AU2018377783A1 (en) * 2017-11-28 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Polypeptide including antigen-binding domain and carrying section
BR112020010248A2 (pt) * 2017-11-28 2020-11-10 Chugai Seiyaku Kabushiki Kaisha molécula de ligação do ligante tendo atividade de ligação do ligante ajustável
WO2019113385A1 (fr) * 2017-12-07 2019-06-13 Janux Therapeutics, Inc. Récepteurs de lymphocytes t modifiés
MX2020008289A (es) * 2018-02-08 2020-09-25 Genentech Inc Moleculas biespecificas de union al antigeno y metodos de uso.
WO2019222275A2 (fr) * 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions et procédés de reprogrammation de tcr utilisant des protéines de fusion inductibles
WO2019222283A1 (fr) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Fraction de liaison pour l'activation conditionnelle de molécules d'immunoglobuline
CN112654633A (zh) 2018-06-22 2021-04-13 科优基因公司 基于细胞因子的可生物活化药物及其使用方法
US20210292427A1 (en) * 2018-07-24 2021-09-23 Cafa Therapeutics Limited Method for treating tumor using immune effector cell
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN113260379B (zh) * 2018-12-21 2022-09-02 浙江时迈药业有限公司 蛋白酶可切割的双特异性抗体及其用途
CN113874396B (zh) * 2019-03-29 2024-01-05 株式会社绿十字 包含抗间皮素抗体、抗cd3抗体或抗egfr抗体的融合蛋白、包含所述融合蛋白的双特异性或三特异性抗体，及其用途
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
KR20220017430A (ko) * 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
AU2020291012A1 (en) * 2019-06-12 2021-12-16 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
JP7455188B2 (ja) * 2019-07-19 2024-03-25 ウーシー・エックスディシー・シンガポール・プライベイト・リミテッド コンジュゲーションのためのポリペプチド複合体及びその応用
CN115427113A (zh) 2020-04-09 2022-12-02 西托姆克斯治疗公司 含有可活化抗体的组合物
CA3181963A1 (fr) 2020-05-04 2021-11-11 Immunorizon Ltd. Constructions d'anticorps tri-specifiques precurseurs et leurs procedes d'utilisation
AU2021291002A1 (en) * 2020-06-19 2022-10-13 F. Hoffmann-La Roche Ag Protease-activated T cell bispecific antibodies
WO2022170619A1 (fr) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anticorps anti-cd3 et leurs méthodes d'utilisation
US20230174995A1 (en) * 2021-10-15 2023-06-08 Cytomx Therapeutics, Inc. Activatable polypeptide complex
CA3234609A1 (fr) * 2021-10-15 2023-04-20 Leila M. BOUSTANY Complexe polypeptidique activable
TW202402794A (zh) * 2022-03-28 2024-01-16 瑞士商赫孚孟拉羅股份公司 經改良的ｆｏｌｒ１蛋白酶可活化之ｔ細胞雙特異性抗體
WO2023192973A1 (fr) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Molécules multispécifiques activables et leurs méthodes d'utilisation
WO2023220647A1 (fr) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Proprotéines de molécules de liaison multispécifiques et leurs utilisations
WO2023222580A1 (fr) 2022-05-16 2023-11-23 Byondis B.V. Nouveaux anticorps masqués
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
ES2755976T3 (es) 2005-02-07 2020-04-24 Roche Glycart Ag Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
JP4949373B2 (ja) * 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
AU2012234335B2 (en) 2011-03-29 2016-09-01 Roche Glycart Ag Antibody Fc variants
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20140004121A1 (en) * 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP2970484B2 (fr) * 2013-03-15 2022-09-21 Amgen Inc. Anticorps hétérodimères bispécifiques
UA119646C2 (uk) * 2013-07-05 2019-07-25 Ґенмаб А/С Гуманізоване антитіло, що зв`язується з сd3 людини
PT3406633T (pt) * 2013-07-25 2022-05-04 Cytomx Therapeutics Inc Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
EP3049440B1 (fr) * 2013-09-25 2020-03-25 Amgen Inc. Anticorps v-c-fc-v-c
CN107108738A (zh) * 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
EP2982692A1 (fr) * 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
JP2018500049A (ja) * 2014-11-11 2018-01-11 アムニクス オペレーティング インコーポレイテッド ターゲティングｘｔｅｎコンジュゲート組成物およびそれを作製する方法
WO2016079081A1 (fr) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Chaînes légères communes et procédés d'utilisation
SG11201707541WA (en) * 2015-03-17 2017-10-30 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto

Also Published As

Publication number Publication date
AU2017237376A1 (en) 2018-08-02
KR20180128407A (ko) 2018-12-03
WO2017162587A1 (fr) 2017-09-28
AR107946A1 (es) 2018-06-28
CO2018007556A2 (es) 2018-07-31
MA43724A (fr) 2018-11-28
EP3433280B1 (fr) 2023-04-19
CA3012422A1 (fr) 2017-09-28
AR120543A2 (es) 2022-02-23
CN108884170A (zh) 2018-11-23
AU2017237376B2 (en) 2024-03-07
KR102444614B1 (ko) 2022-09-21
PT3433280T (pt) 2023-06-15
SG11201808085WA (en) 2018-10-30
CR20180453A (es) 2018-12-05
BR112018016281A2 (pt) 2019-01-02
EP3433280A1 (fr) 2019-01-30
PE20181891A1 (es) 2018-12-11

Similar Documents

Publication Publication Date Title
MA43724B1 (fr) Molécules bispécifiques de cellules t activées par une protéase
PH12018502035A1 (en) Protease-activated t cell bispecific molecules
MA40972B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
MA35448B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
PH12018502613A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
WO2019035880A8 (fr) Exosomes de cellules souches mésenchymateuses purifiées et leurs utilisations
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
EA201890172A1 (ru) Тау-связывающие антитела
MA31904B1 (fr) Anticorps bispecifiques bivalents
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
FR2942798B1 (fr) Peptides utilisables pour le traitement de la leucemie lymphoide chronique
EA202090044A1 (ru) Очистка идуронат-2-сульфатазы
DK1511761T3 (da) Fremgangsmåde til fremstilling af cykliske peptider
MA41758A (fr) Procédés de traitement de l'infertilité
MX2019003077A (es) Anticuerpos novedosos contra el factor xi y sus usos.
JO2991B1 (ar) بروتينات رابطة لمولد ضد المستقبل ايه للانترليوكين 17